Amendments to the Abstract:

Please replace the Abstract with the following amended Abstract:

Abstract of the Disclosure

A subject of the present invention is to find utility of a A combination of a Rho kinase inhibitor and prostaglandins a prostaglandin as a therapeutic agent for treating glaucoma. A method for treating glaucoma comprising administering to a patient pharmaceutically effective amounts of a Rho kinase inhibitor and a prostaglandin. Actions The actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the a Rho kinase inhibitor with prostaglandins a prostaglandin. For the administration mode[[,]]each drug Each of the Rho kinase inhibitor and the prostaglandin can be administered in combination or in a mixture.